This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rybak, S. M. Articles by Sausville, E. A. Search for Related Content PubMed PubMed Citation Articles by Rybak, S. M. Articles by Sausville, E. A.

"Vasocrine" Formation of Tumor Cell-lined Vascular Spaces

Implications for Rational Design of Antiangiogenic Therapies¹

Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis [S. M. R., M. G. H., G. K., E. A. S.] and Science Applications International Corporation-Frederick [E. S., S. D. B., D. L. N., G. M., D. K.], National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702

Here we report that B16F10 murine melanoma cells mimic endothelial cell behavior and the angiogenic process in vitro and in vivo. Cord formation in vitro by tumor cells is stimulated by hypoxia and vascular endothelial growth factor (VEGF) and inhibited by antibodies against VEGF and the VEGF KDR receptor (VEGF receptor 2). We define regulation of tumor cell-derived vascular space formation by these vasoactive compounds as "vasocrine" stimulation. ICRF 159 (Razoxane; NSC 129943) prevents tumor cell but not endothelial cell cord formation in vitro, and the antiangiogenic drug TNP-470 (NSC 642492) inhibits endothelial but not tumor cell cord formation in vitro. Both drugs inhibit formation of blood-filled vascular spaces in vivo. These results bear on the anticipated action of ICRF 159 in human clinical trials and novel strategies for targeting tumor blood supplies.

This article has been cited by other articles:

				L.-M. Postovit, E. A. Seftor, R. E.B. Seftor, and M. J.C. Hendrix Influence of the Microenvironment on Melanoma Cell Fate Determination and Phenotype Cancer Res., August 15, 2006; 66(16): 7833 - 7836. [Abstract] [Full Text] [PDF]

				D. W.J. van der Schaft, F. Hillen, P. Pauwels, D. A. Kirschmann, K. Castermans, M. G.A. oude Egbrink, M. G.B. Tran, R. Sciot, E. Hauben, P. C.W. Hogendoorn, et al. Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia Cancer Res., December 15, 2005; 65(24): 11520 - 11528. [Abstract] [Full Text] [PDF]

				A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther., November 1, 2005; 4(11): 1717 - 1728. [Abstract] [Full Text] [PDF]

				E. di Tomaso, D. Capen, A. Haskell, J. Hart, J. J. Logie, R. K. Jain, D. M. McDonald, R. Jones, and L. L. Munn Mosaic Tumor Vessels: Cellular Basis and Ultrastructure of Focal Regions Lacking Endothelial Cell Markers Cancer Res., July 1, 2005; 65(13): 5740 - 5749. [Abstract] [Full Text] [PDF]

				G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311. [Abstract] [Full Text] [PDF]

				D. W. J. van der Schaft, R. E. B. Seftor, E. A. Seftor, A. R. Hess, L. M. Gruman, D. A. Kirschmann, Y. Yokoyama, A. W. Griffioen, and M. J. C. Hendrix Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells J Natl Cancer Inst, October 6, 2004; 96(19): 1473 - 1477. [Abstract] [Full Text] [PDF]